Executive Gov
  • Home
  • Acquisition & Procurement
  • Agencies
    • DoD
    • Intelligence
    • DHS
    • Civilian
    • Space
  • Cybersecurity
  • Technology
  • Awards
  • News
  • About
  • Wash100
  • Contact Us
    • Advertising
    • Submit your news
No Result
View All Result
Executive Gov
  • Home
  • Acquisition & Procurement
  • Agencies
    • DoD
    • Intelligence
    • DHS
    • Civilian
    • Space
  • Cybersecurity
  • Technology
  • Awards
  • News
  • About
  • Wash100
  • Contact Us
    • Advertising
    • Submit your news
No Result
View All Result
Executive Gov
No Result
View All Result
Home News

FDA Works to Find Treatments for COVID-19; Alex Azar Quoted

by Sarah Sybert
December 6, 2022
in News, Press Releases
FDA Works to Find Treatments for COVID-19; Alex Azar Quoted
FDA Works to Find Treatments for COVID-19; Alex Azar Quoted

The U.S. Food and Drug Administration (FDA) has responded to the COVID-19 pandemic by facilitating medical countermeasures to treat and prevent the disease and surveilling the medical product and food supply chains for potential shortages or disruptions and helping to mitigate impacts, the FDA reported on Friday.

Table of Contents

  • You might also like
  • GSA Seeks Comments on Draft AI Data Safeguarding Clause
  • Kelly Hammett Named Air Force Nuclear Weapons Center Executive Director
  • DOE’s ARPA-E Unveils $72M for Critical Minerals, Magnet R&D Projects

You might also like

GSA Seeks Comments on Draft AI Data Safeguarding Clause

Kelly Hammett Named Air Force Nuclear Weapons Center Executive Director

DOE’s ARPA-E Unveils $72M for Critical Minerals, Magnet R&D Projects

"President Trump's aggressive response and bold actions to keep Americans safe from COVID-19 bought us precious time to advance therapeutics and other necessary tools," said HHS Secretary Alex Azar.

President Trump has directed the FDA to continue its work with the public and private sector to provide safe and effective drugs to patients, including those infected with COVID-19. The FDA has been working closely with other government agencies and academic centers that have investigated the use of the drug chloroquine to determine whether it can be used to treat patients with mild-to-moderate COVID-19. 

If the drug is approved, it could potentially reduce the duration of symptoms, as well as viral shedding, which can help prevent the spread of disease. Studies are underway to determine the efficacy in using chloroquine to treat COVID-19.

“Disseminating information about promising off-label uses of drugs we already have, investigating their effectiveness, and pursuing other therapeutics will help give American healthcare providers the tools they need to save lives. As we have always seen when America has faced a serious threat, American industry, academic institutions and government are coming together to deliver us what we need to win," added Azar.

The FDA wants to assure the American public that the agency will continue to work with partners across the U.S. government and regulated industry to expedite the development and availability of critical medical products to prevent and treat the virus, including repurposing existing therapies that may help treat patients with COVID-19.

About FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Stay connected via Google News
Follow us for the latest travel updates and guides.
Add as preferred source on Google
Share5Tweet19

Recommended For You

GSA Seeks Comments on Draft AI Data Safeguarding Clause

by Jane Edwards
June 19, 2026
General Services Administration logo. GSA has started soliciting feedback on a draft AI data safeguarding clause.

GSA has sought feedback on a draft AI data safeguarding clauseThe proposed clause outlines requirements for LLM use in contractingThe 2026 FedCiv Summit will examine AI, cloud and...

Read moreDetails

Kelly Hammett Named Air Force Nuclear Weapons Center Executive Director

by Miles Jamison
June 19, 2026
Kelly Hammett. The Air Force Nuclear Weapons Center has appointed Kelly Hammett as executive director.

Kelly Hammett has been named executive director of the Air Force Nuclear Weapons CenterHe will advise AFNWC leadership on the acquisition, sustainment and modernization of nuclear weapons systemsHammett...

Read moreDetails

DOE’s ARPA-E Unveils $72M for Critical Minerals, Magnet R&D Projects

by Jane Edwards
June 19, 2026
Conner Prochaska. The ARPA-E director commented on selected projects to advance mineral discovery and magnets production.

DOE has announced $72 million in funding for critical minerals and magnet R&D ROCKS and MAGNITO target mineral discovery and magnet innovationSouth Dakota Mines and the University of Houston...

Read moreDetails

DIA Seeks Proposals for DORE3 Contract

by Miles Jamison
June 19, 2026
DIA logo. The Defense Intelligence Agency has issued a request for proposals for the DORE3 contract.

DIA has issued a request for proposals for the DORE3 contractThe contract covers 11 mission support areas, including collection concept development, data sciences support and program supportThe contractor...

Read moreDetails

USINDOPACOM Chief Adm. Samuel Paparo Makes Case for 2027 Budget, Cites Chinese Military Woes

by Jamie Bennet
June 19, 2026
Samuel Paparo. The USINDOPACOM Commander stressed the need for increased military preparedness against China.

U.S. Navy Adm. Samuel Paparo reportedly sent a private report to Congress detailing the needs of the Indo-Pacific Command to counter threats from ChinaUSINDOPACOM is requesting $122 billion...

Read moreDetails
Sign Up For Our Newsletter
Subscribe to our mailing list to receives daily updates direct to your inbox!
Invalid email address
Your privacy is guranteed.
Thanks for subscribing!

Sponsors

About ExecutiveGov

ExecutiveGov, published by Executive Mosaic, is a site dedicated to the news and headlines in the federal government. ExecutiveGov serves as a news source for the hot topics and issues facing federal government departments and agencies such as Gov 2.0, cybersecurity policy, health IT, green IT and national security. We also aim to spotlight various federal government employees and interview key government executives whose impact resonates beyond their agency.

CATEGORIES

  • Acquisition & Procurement
  • Announcements
  • Articles
  • Artificial Intelligence
  • Awards
  • Big Data & Analytics News
  • C4ISR
  • Civilian
  • Cloud
  • Contract Awards
  • Cybersecurity
  • Defense And Intelligence
  • Defense Security Cooperation
  • DHS
  • Digital Assets
  • Digital Modernization
  • DoD
  • Events
  • Executive Moves
  • Executive Spotlights
  • Federal Civilian
  • Financial Reports
  • Foreign Military Sales
  • General News
  • GovCon Expert
  • Government Technology
  • GSA
  • Healthcare IT
  • Industry News
  • Intelligence
  • Legislation
  • M&A Activity
  • National Security
  • News
  • Policy Updates
  • Press Releases
  • Profiles
  • Space
  • Videos
  • Wash100
Sign Up For Our Newsletter
Subscribe to our mailing list to receives daily updates direct to your inbox!
Invalid email address
Your privacy is guranteed.
Thanks for subscribing!

Copyright 2026 Executive Mosaic. All Rights Reserved.

No Result
View All Result
  • Home
  • Acquisition & Procurement
  • Agencies
    • DoD
    • Intelligence
    • DHS
    • Civilian
    • Space
  • Cybersecurity
  • Technology
  • Awards
  • News
  • About
  • Wash100
  • Contact Us
    • Advertising
    • Submit your news

Copyright 2026 Executive Mosaic. All Rights Reserved.

Get your free GovCon news!

Get your latest GovCon news and insights. Become a VIP and subscribe to the GovConWire Daily News.

Invalid email address
We promise not to spam you. You can unsubscribe at any time.
Thanks for subscribing!